Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

Posted by Trevor Kearing on Mar 22nd, 2025

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a report released on Thursday morning. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research note on Monday, March 10th.

Get Our Latest Research Report on Aethlon Medical

Aethlon Medical Price Performance

Aethlon Medical stock opened at $0.43 on Thursday. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $1.85. The firm has a 50 day simple moving average of $0.58 and a 200-day simple moving average of $0.50. The stock has a market capitalization of $6.22 million, a PE ratio of -0.27 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD – Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.09. On average, analysts forecast that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AEMD. Boothbay Fund Management LLC bought a new position in Aethlon Medical in the fourth quarter valued at approximately $186,000. Virtu Financial LLC bought a new position in Aethlon Medical in the fourth quarter valued at approximately $81,000. Sassicaia Capital Advisers LLC bought a new position in Aethlon Medical in the fourth quarter valued at approximately $31,000. Allegiance Financial Group Advisory Services LLC bought a new position in Aethlon Medical in the fourth quarter valued at approximately $26,000. Finally, Renaissance Technologies LLC bought a new position in Aethlon Medical in the fourth quarter valued at approximately $25,000. Institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

(Get Free Report)

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.